Overt Hepatic Encephalopathy Market is expected to register 11.2% CAGR during the forecast period of 2019 to 2025 and held a market value of USD 54.28 Million in 2018.
Hepatic encephalopathy is a neuropsychiatric complication that occurs in patients with end-stage liver disease. It develops in approximately 50% of patients who have cirrhosis. Factors responsible for development of over hepatic encephalopathy include gastrointestinal bleeding, metabolic disturbance, and liver infection. Around 30 million people in the US are diagnosed with some form of overt hepatic encephalopathy disease annually.
The global overt hepatic encephalopathy market is driven by factors such as the prevalence of cirrhosis, rising cases of road traffic accidents, and increasing healthcare expenditure. For instance, according to the World Health Organization (WHO) report 2018, about 30–45% patients suffer from overt hepatic encephalopathy in the US. On the other hand, the availability of traditional treatment methods is expected to hamper the growth of the global market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to maintain their position in the market.
Segmentation
The Global Overt Hepatic Encephalopathy Market has been segmented based on type, disease security, diagnosis, treatment, end user, and region.
The global overt hepatic encephalopathy market, based on type, has been divided into covert and overt. The overt segment is expected to hold a major share in the market due to the rising prevalence of liver disease globally.
The global overt hepatic encephalopathy market, based on disease security, has been segmented into Type A, Type B, and Type C.
The global overt hepatic encephalopathy market, based on diagnosis, has been segmented into blood tests, liver function test, detection of serum ammonia levels, encephalogram, and others.
The global overt hepatic encephalopathy market, based on treatment, is divided into lactulose, antibiotics, probiotics, branched-chain amino acids, liver transplantation, and others.
Based on end user, the global overt hepatic encephalopathy market is segmented into hospitals & clinics, research institutes, surgical centers, and others.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The overt hepatic encephalopathy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European overt hepatic encephalopathy market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The overt hepatic encephalopathy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The overt hepatic encephalopathy market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The Key Players operating in the Global Overt Hepatic Encephalopathy Market are Alfa Wassermann S.P.A, Cosmo Pharmaceuticals S.P.A, Horizon Pharma Plc., KannaLife Sciences, Inc., Ocer Therapeutics, Rebiotix Inc., Spherium Biomed S.L, Umecrine Cognition AB, ASKA Pharmaceutical, Mallinckrodt, Valeant, and Norgine B.V.
Global Overt Hepatic Encephalopathy Market, by Type
Global Overt Hepatic Encephalopathy Market, by Disease Severity
Global Overt Hepatic Encephalopathy Market, by Diagnosis
- Blood Tests
- Liver Function Test
- Detection of Serum Ammonia Levels
- Encephalogram
- Others
Global Overt Hepatic Encephalopathy Market, by Treatment
- Lactulose
- Antibiotics
- Probiotics
- Branched-Chain Amino Acids
- Liver Transplantation
- Others
Global Overt Hepatic Encephalopathy Market, by End User
- Hospitals & Clinics
- Research Institutes
- Surgical Centers
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization